Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) EBITDA (2016 - 2025)

Historic EBITDA for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to -$69.8 million.

  • Ocular Therapeutix's EBITDA fell 3793.1% to -$69.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$270.0 million, marking a year-over-year decrease of 5718.62%. This contributed to the annual value of -$270.0 million for FY2025, which is 5718.68% down from last year.
  • Per Ocular Therapeutix's latest filing, its EBITDA stood at -$69.8 million for Q4 2025, which was down 3793.1% from -$68.7 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's EBITDA peaked at -$17.8 million during Q1 2022, and registered a low of -$69.8 million during Q4 2025.
  • Its 5-year average for EBITDA is -$34.0 million, with a median of -$21.1 million in 2022.
  • Its EBITDA has fluctuated over the past 5 years, first surged by 1184.0% in 2022, then plummeted by 15224.94% in 2024.
  • Over the past 5 years, Ocular Therapeutix's EBITDA (Quarter) stood at -$18.0 million in 2021, then fell by 7.27% to -$19.4 million in 2022, then fell by 3.56% to -$20.0 million in 2023, then plummeted by 152.25% to -$50.6 million in 2024, then plummeted by 37.93% to -$69.8 million in 2025.
  • Its last three reported values are -$69.8 million in Q4 2025, -$68.7 million for Q3 2025, and -$67.6 million during Q2 2025.